XSWX:ROG (Switzerland)
Business Description
Roche Holding AG
NAICS : 325412
SIC : 2834
Grenzacherstrasse 124, Basel, CHE, 4070
Compare
Compare
Traded in other countries / regions
RHO.Germany
•
ROG N.Mexico
•
RO.Switzerland
•
0QOK.UK
•
RHHBF.USA
Description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.1 | |||||
Debt-to-EBITDA | 1.2 | |||||
Interest Coverage | 38.41 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.25 | |||||
Beneish M-Score | -2.86 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.4 | |||||
3-Year EBITDA Growth Rate | 6.4 | |||||
3-Year EPS without NRI Growth Rate | 9.9 | |||||
3-Year FCF Growth Rate | 2.9 | |||||
3-Year Book Growth Rate | -1.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Industry Rank | 4.6 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 2.45 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.18 | |||||
9-Day RSI | 39.06 | |||||
14-Day RSI | 42.89 | |||||
6-1 Month Momentum % | -7.6 | |||||
12-1 Month Momentum % | -10.93 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.11 | |||||
Quick Ratio | 0.8 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 143.38 | |||||
Days Sales Outstanding | 64.05 | |||||
Days Payable | 70.62 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.94 | |||||
Dividend Payout Ratio | 0.53 | |||||
3-Year Dividend Growth Rate | 3.1 | |||||
Forward Dividend Yield % | 2.94 | |||||
5-Year Yield-on-Cost % | 3.34 | |||||
3-Year Average Share Buyback Ratio | 2.1 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 67.94 | |||||
Operating Margin % | 30.48 | |||||
Net Margin % | 22.77 | |||||
ROE % | 50.26 | |||||
ROA % | 16.47 | |||||
ROIC % | 21.21 | |||||
ROC (Joel Greenblatt) % | 74.74 | |||||
ROCE % | 32.41 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 17.9 | |||||
Forward PE Ratio | 15.15 | |||||
PE Ratio without NRI | 17.9 | |||||
Shiller PE Ratio | 24.7 | |||||
Price-to-Owner-Earnings | 17.05 | |||||
PEG Ratio | 2.8 | |||||
PS Ratio | 4.1 | |||||
PB Ratio | 10.07 | |||||
Price-to-Tangible-Book | 110.35 | |||||
Price-to-Free-Cash-Flow | 14.9 | |||||
Price-to-Operating-Cash-Flow | 11.9 | |||||
EV-to-EBIT | 14.86 | |||||
EV-to-Forward-EBIT | 12.87 | |||||
EV-to-EBITDA | 12.24 | |||||
EV-to-Forward-EBITDA | 11.19 | |||||
EV-to-Revenue | 4.39 | |||||
EV-to-Forward-Revenue | 4.4 | |||||
EV-to-FCF | 15.88 | |||||
Price-to-Projected-FCF | 1.69 | |||||
Price-to-DCF (Earnings Based) | 1.32 | |||||
Price-to-DCF (FCF Based) | 1.1 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.07 | |||||
Price-to-Graham-Number | 9.38 | |||||
Earnings Yield (Greenblatt) % | 6.73 | |||||
Forward Rate of Return (Yacktman) % | 11.53 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 64,383 | ||
EPS (TTM) (CHF) | 17.69 | ||
Beta | 0.79 | ||
Volatility % | 18.52 | ||
14-Day RSI | 42.89 | ||
14-Day ATR (CHF) | 6.218114 | ||
20-Day SMA (CHF) | 324.6525 | ||
12-1 Month Momentum % | -10.93 | ||
52-Week Range (CHF) | 298.3 - 404.2 | ||
Shares Outstanding (Mil) | 800.58 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Roche Holding AG Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |